Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 21;12:749369. doi: 10.3389/fimmu.2021.749369

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Xu, Liu, Zhou, Zou and Xu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immunity analysis of APOBEC3A high- and low-expression cohorts in ovarian cancer (OC) patients. (A) The correlation of APOBEC3A with ImmuneScore, Wilcoxon rank sum was applied for the significance test. (B) Violin plot showed the ratio differentiation of 22 types of immune cells between OC tumor samples with high or low expression relative to the median of APOBEC3A expression, and Wilcoxon rank sum was applied for the significance test. (C, D) Kaplan–Meier curves show the independent relevance between overall survival time and Macrophage M0 and Macrophage M1. (E) The correlation between common inhibitory immune checkpoints (ICPs) and APOBEC3A high- and low-expression cohorts; Wilcoxon rank sum was applied for the significance test. The results showed that the expression of ICPs was all significantly positive-correlated with APOBEC3A group. ***p < 0.001. (F) The correlation of APOBEC3A with Immunophenoscores (IPS) in OC patients who have not received anti-CTLA4 or anti-PD-1 immunotherapy. (G) The correlation of APOBEC3A with IPS in OC patients who have only received anti-PD-1 immunotherapy. (H) The correlation of APOBEC3A with IPS in OC patients who have only received anti-CTLA4 immunotherapy. (I) The correlation of APOBEC3A with IPS in OC patients who have received anti-CTLA4 combined with anti-PD-1 immunotherapy. (J) ssGSEA for the association between immune cell subpopulations and related functions. ***p < 0.001, **p < 0.01, *p < 0.05. (K) Heatmap for immune responses based on ssGSEA among APOBEC3A high- and low-expression group.